WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H535749
CAS#: 973-99-9
Description: Prosultiamine hydrochloride is abiaoctive chemical.
Hodoodo Cat#: H535749
Name: Prosultiamine hydrochloride
CAS#: 973-99-9
Chemical Formula: C15H25ClN4O2S2
Exact Mass: 392.11
Molecular Weight: 392.961
Elemental Analysis: C, 45.85; H, 6.41; Cl, 9.02; N, 14.26; O, 8.14; S, 16.32
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Prosultiamine hydrochloride
IUPAC/Chemical Name: Formamide, N-((4-amino-2-methyl-5-pyrimidinyl)methyl)-N-(4-hydroxy-1-methyl-2-(propyldithio)-1-butenyl)-, monohydrochloride
InChi Key: DURRYBGTQKKQBR-JHGYPSGKSA-N
InChi Code: InChI=1S/C15H24N4O2S2.ClH/c1-4-7-22-23-14(5-6-20)11(2)19(10-21)9-13-8-17-12(3)18-15(13)16;/h8,10,20H,4-7,9H2,1-3H3,(H2,16,17,18);1H/b14-11+;
SMILES Code: O=CN(CC1=CN=C(C)N=C1N)/C(C)=C(SSCCC)\CCO.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 392.96 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Matsuo T, Miyata Y, Nakamura T, Satoh K, Sakai H. Prosultiamine for treatment of lower urinary tract dysfunction accompanied by human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis. Int J Urol. 2018 Jan;25(1):54-60. doi: 10.1111/iju.13468. Epub 2017 Oct 1. PMID: 28965354.
2: Nishiura Y, Nakamura T, Fukushima N, Nakamura H, Ida H, Aramaki T, Eguchi K. Disulfide-mediated apoptosis of human T-lymphotrophc virus type-I (HTLV-I)-infected cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. Antivir Ther. 2009;14(4):533-42. PMID: 19578238.
3: Nakamura T, Matsuo T, Fukuda T, Yamato S, Yamaguchi K, Kinoshita I, Matsuzaki T, Nishiura Y, Nagasato K, Narita-Masuda T, Nakamura H, Satoh K, Sasaki H, Sakai H, Kawakami A. Efficacy of prosultiamine treatment in patients with human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: results from an open-label clinical trial. BMC Med. 2013 Aug 15;11:182. doi: 10.1186/1741-7015-11-182. PMID: 23945290; PMCID: PMC3826868.
4: Kira J. Therapeutic benefits of an oral vitamin B1 derivative for human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). BMC Med. 2013 Aug 15;11:183. doi: 10.1186/1741-7015-11-183. PMID: 23945332; PMCID: PMC3826871.
5: Oka H, Tsuzuki K, Takebayashi H, Kojima Y, Daimon T, Sakagami M. Olfactory changes after endoscopic sinus surgery in patients with chronic rhinosinusitis. Auris Nasus Larynx. 2013 Oct;40(5):452-7. doi: 10.1016/j.anl.2012.12.001. Epub 2013 Jan 11. PMID: 23312885.
6: Nakashima T, Kidera K, Miyazaki J, Kuratomi Y, Inokuchi A. Smell intensity monitoring using metal oxide semiconductor odor sensors during intravenous olfaction test. Chem Senses. 2006 Jan;31(1):43-7. doi: 10.1093/chemse/bjj004. Epub 2005 Dec 1. PMID: 16322087.
7: Hirakawa K. [Prognosis in olfaction disorders]. Nihon Jibiinkoka Gakkai Kaiho. 2004 Oct;107(10):937-42. Japanese. doi: 10.3950/jibiinkoka.107.937. PMID: 15658010.
8: Saito K, Takahashi M, Fukuta K, Tachibana E, Yoshida J. Recovery of olfactory function after an anterior craniofacial approach. Skull Base Surg. 1999;9(3):201-6. doi: 10.1055/s-2008-1058147. PMID: 17171090; PMCID: PMC1656739.
9: Kasuga Y, Nishimura K, Go H, Nakazaki K, Shimizu S, Kanezawa K, Tanaka M, Oshima T, Morioka I. Severe olfactory and gustatory dysfunctions in a Japanese pediatric patient with coronavirus disease (COVID-19). J Infect Chemother. 2020 Sep 30:S1341-321X(20)30350-0. doi: 10.1016/j.jiac.2020.09.030. Epub ahead of print. PMID: 33039267; PMCID: PMC7526635.
10: Zusho H. Olfactometry in Japan. Rhinology. 1983 Sep;21(3):281-5. PMID: 6635477.